Healthcare >> CEO Interviews >> October 12, 2001
DR. IAN E. MAXWELL is presently the CEO of Avantium Technologies, a high
technology company with laboratories in the Netherlands and software
development facilities in the US and UK. Prior to this position he was a
global technology manager of the catalyst research and development group
at the Shell Research and Technology Center, Amsterdam. He had
accumulated some 25 years of experience in Shell research covering the
fields of fundamental catalysis, exploratory and development chemicals,
process modeling and high throughput technologies. Some of this
experienced was gained in the US at the Shell technology center in
Houston. He is also actively involved in contacts with Universities and
other scientific/technical institutes. At the academic/industrial
interface he is a member of the Industrial Advisory Board of the
Netherlands Institute of Catalysis, NIOK and of the Board of the new
Institute of Applied Catalysis, iAC in the UK. He is on the editorial
boards of a number of International Journals in the fields of catalysis
and materials science and has numerous publications and patents in these
fields. Profile
TWST: Could you begin with a brief historical sketch and an overview ofAvantium Technologies?
Dr. Maxwell: Avantium was formed in February 2000. It's actually a spin
out company from Shell.